Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Use of intravitreal bevacizumab in rubeosis, rubeotic glaucoma and choroidal neovascularisation: our experience

Poster Details

First Author: N. Chittajallu UK

Co Author(s): A. Ghaloo   P. Prakash                 

Abstract Details


To determine the response to intravitreal Bevacizumab injections in eyes with rubeosis, rubeotic glaucoma and non age related macular degeneration (AMD) causes of choroidal neovascularisation (CNV) where licensed alternatives are not available in the United Kingdom.


The study was performed in a district general hospital in the United Kingdom.


A retrospective audit was performed reviewing the medical records of patients who received intravitreal Bevacizumab injections for rubeosis, rubeotic glaucoma and non AMD causes of CNV. A total of 22 eyes were included. 18 rubeotic and 4 CNV cases were treated. Rubeosis was secondary to Diabetes (11 eyes), ischaemic central retinal vein occlusion (6 eyes) without macular oedema, central retinal artery occlusion (1 eye). 7 out of 18 eyes had rubeotic glaucoma. CNV was secondary to Pseudoxanthoma Elasticum (1eye), Punctate inner choroidopathy(1 eye), Birdshot retinopathy(1 eye) and one was idiopathic. Parameters documented were visual acuity, intraocular pressure, rubeosis and CNV.


Response in rubeosis: Visual acuity improved in 2 eyes(11.5%), stable in 14 eyes(77%) and dropped in 2 eyes(11.5%) despite treatment . Rubeosis regressed in 9 eyes (50%) whereas 6 (33.3%) did not respond. 3 cases had no documentation of rubeosis. All these patients had Pan Retinal Photocoagulation as clinically indicated. 4 (57.14%) out of 7 eyes of rubeotic glaucoma had reduction in intraocular pressure after treatment. Response in CNV cases: Visual acuity improved in 1 case (25%) and was stable in 3 eyes (75%). CNV resolved in 3 eyes (75%) and in 1 case there was no documentation of CNV.


Intravitreal Bevacizumab is a good alternative to treat and control rubeotic glaucoma where licensed alternatives are not available. It has also shown to be effective in regression of choroidal neovascularisation secondary to Pseudoxanthoma Elasticum, Punctate inner choroidopathy and Birdshot retinopathy.

Financial Disclosure:


Back to Poster listing